Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PRAX with free AI briefings, catalyst countdowns, and dilution alerts.

PRAX · Praxis Precision Medicines, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.7B Cash, Jun 2026
60mo Cash Runway (est.)
+33% Share Count, 1 Year
Follow PRAX by email Get an email when PRAX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PRAX, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoAOptions-implied move
2027-01-29 — SCN2A and SCN8A-DEE and RPD designation for Dravet Syndrome NDA 66% ±37% by Feb 19

Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Oct 2). It prices every move until that expiry, not only the FDA decision.

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area and cash runway. Not investment advice. See the full PDUFA calendar →

📣 What PRAX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

💰 Cash Runway & Dilution Risk

PRAX reported $1.7B in cash and short-term investments (as of Jun 30, 2026) and used about $82.5M/quarter in operations, an estimated runway of 60.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 42 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PRAX files for a raise →

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2025-12-31 — NDA +51.2% -0.8% -1.5%

Browse all historical PDUFA outcomes →

Get the full PRAX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PRAX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.